Cas:887595-17-7 (4-Pyridin-2-yl-butyl)-hydrazine manufacturer & supplier

Chemical Name:(4-Pyridin-2-yl-butyl)-hydrazine

CAS.NO:887595-17-7

Synonyms:4-(PYRIDIN-2-YL)BUTYLHYDRAZINE HYDROCHLORIDE;Pyridine,2-(4-hydrazinylbutyl);Pyridine,2-(4-hydrazinobutyl)-(9CI);(4-Pyridin-2-yl-butyl)-hydrazine

Molecular Formula:C₉H₁₅N₃

Molecular Weight:165.23500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:332.8ºC at 760 mmHg

Density:1.026g/cm3

Index of Refraction:1.537

PSA:50.94000

Exact Mass:165.12700

LogP:1.95880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(PYRIDIN-2-YL)BUTYLHYDRAZINE HYDROCHLORIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-Pyridin-2-yl-butyl)-hydrazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(PYRIDIN-2-YL)BUTYLHYDRAZINE HYDROCHLORIDE Use and application,4-(PYRIDIN-2-YL)BUTYLHYDRAZINE HYDROCHLORIDE technical grade,usp/ep/jp grade.

Related News: Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. (4-Pyridin-2-yl-butyl)-hydrazine manufacturer The findings were published June 14 in the journal Nature Aging. (4-Pyridin-2-yl-butyl)-hydrazine supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. (4-Pyridin-2-yl-butyl)-hydrazine vendor This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. (4-Pyridin-2-yl-butyl)-hydrazine factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.